: Continues to be a high-conviction pick for structural growth exposure and is among the most traded stocks in April 2026.
: Remains the UK's most valuable company (£234bn cap). It is favored for its strong oncology and respiratory pipeline and long-term healthcare growth theme.
: Offers instant exposure to the 50 highest-yielding FTSE 100/250 stocks, currently yielding approximately 4.6%.
: Highly ranked for its exposure to increased global defense spending. Income & High-Yield Shares